Plain-English translation of NCT06339060 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new way to treat locally advanced esophageal cancer using three treatments together: chemotherapy (strong cancer-fighting drugs), radiation therapy, and an immunotherapy drug called Camrelizumab that helps your immune system fight cancer. The study compares two approaches: one group receives all three treatments and then may avoid surgery if their cancer completely disappears, while the other group receives the same three treatments followed by surgery to remove the esophagus.
Currently, surgery to remove the esophagus is the standard treatment after chemotherapy and radiation, but it is a major operation with serious side effects and recovery challenges. This trial is exploring whether the medication, combined with chemotherapy and radiation, can be effective enough that some patients can keep their esophagus and avoid surgery altogether.
You likely qualify if…
You likely don't qualify if…
If you join, you will receive the medication by IV infusion twice, along with chemotherapy drugs and radiation therapy over several weeks. After treatment, your doctors will check whether your cancer has completely disappeared using imaging tests. If it has, you enter a monitoring phase where you have regular check-ups instead of surgery; if cancer is detected, you then have surgery. Throughout the trial, you will have follow-up visits to monitor your health, side effects, and how well the cancer remains controlled, possibly for years after treatment.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China